Genmab A/S (OTCMKTS:GNMSF – Get Free Report) shares gapped up prior to trading on Tuesday. The stock had previously closed at $388.5150, but opened at $439.05. Genmab A/S shares last traded at $439.05, with a volume of 68 shares.
Genmab A/S Stock Performance
The company has a current ratio of 2.46, a quick ratio of 2.44 and a debt-to-equity ratio of 0.81. The firm has a fifty day moving average price of $360.98 and a 200 day moving average price of $302.82. The firm has a market cap of $35.04 billion, a PE ratio of 44.63 and a beta of 0.79.
About Genmab A/S
Genmab A/S is a Denmark-based biotechnology company focused on discovering, developing and commercializing antibody-based medicines for the treatment of cancer and other serious diseases. The company uses proprietary technologies to create differentiated antibodies and antibody-drug conjugates designed to engage the immune system or target specific disease-related proteins.
Genmab’s technologies include the DuoBody platform for generating bispecific antibodies, as well as the HexaBody platform for developing antibodies with enhanced activity.
Recommended Stories
- Five stocks we like better than Genmab A/S
- NXP Semiconductors Falls After Strong Earnings—Is the Sell-Off Overdone?
- GE Vernova’s Reservations Are Turning Into Real Orders—But the Market Still Wants More.
- Where’s the Beef? Trian-Led Buyout Proposal Values Wendy’s at $1.4B, But Is It Enough?
- Constellation Energy’s Nuclear Expansion Gets a $5 Billion Opening, Not a Guarantee
Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.
